Genmab — November 2014
-
phase II som vil evaluere dara i 3 forskellige behandlingsregimenter.. Syntes det er fint de starter med et phase II i smoldering
-
og ikke bare kører et phase III. Det er vigtigt at lave forarbedjet ordentligt i denne indikation da den er lidt anderledes end normal MM. Men det potentielle markedspotentiale er enormt.
-
282 brudt nu
-
284
-
flot luk omkring 285
-
Update på phase III len/dex/dara. behandlingsforløb er nu begrænset til 2 år. http://www.clinicaltrials.gov/ct2/show/NCT02252172?term=daratumumab&rank=7&submit_fld_opt=
-
Spændende. Mon det er for at få hurtigere data ud?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind